TOMM6-Interacting Compounds for Mitochondrial Dysfunction and Protein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nervous system diseases, atherosclerosis, Hepatitis B infection, and HPV infection are inadequate, with existing therapies offering limited efficacy and significant side effects, and there is a need for disease-modifying approaches that target mitochondrial dysfunction and protein aggregation.
Innovation Solution
Development of TOMM6-interacting compounds that bind, induce, or stabilize the Translocase of Outer Membrane 6kDa subunit homologue (TOMM6) to prevent mitochondrial dysfunction, toxic protein aggregation, and inhibit amyloidogenic protein assembly, thereby treating or preventing the mentioned conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for nervous system diseases are used, then disease symptoms can be managed, but they cannot modify disease progression and have major side effects
Solution Approach 1:
The patent uses TOMM6 as an intermediary target - a mitochondrial outer membrane protein involved in protein import - to mediate the therapeutic effect. By developing compounds that specifically interact with TOMM6, the invention creates a new pathway for disease modification that avoids the side effects of conventional treatments. The TOMM6-interacting compounds act as intermediaries between the administered drug and the pathological processes, enabling selective modulation of mitochondrial function and protein aggregation without affecting other systems.
Solution Approach 2:
The invention changes the therapeutic parameter from symptomatic management to disease modification by targeting mitochondrial protein import machinery. The TOMM6-interacting compounds alter the fundamental parameter of mitochondrial function and protein aggregation dynamics, representing a paradigm shift from managing symptoms to modifying the underlying disease progression mechanism.
2Quantity of substance
If approaches that only interfere with Abeta plaque formation are used, then plaque accumulation may be reduced, but they do not demonstrate efficacy in retarding AD progression and show major side effects
Solution Approach 1:
The patent extracts the therapeutic focus from merely reducing Abeta plaque quantity to addressing the underlying mitochondrial dysfunction and protein aggregation mechanisms. By taking out the TOMM6 target from the conventional amyloid-centric approach and developing specific TOMM6-interacting compounds, the invention creates a more comprehensive treatment that addresses multiple pathological features simultaneously, including protein aggregation, mitochondrial dysfunction, and neuroprotection.
3Reliability
If TOMM6-interacting compounds are developed, then mitochondrial dysfunction and protein aggregation can be targeted, but new therapeutic agents with unknown safety profiles are introduced
Solution Approach 1:
The TOMM6-interacting compounds enable the cell's own mitochondrial import machinery to function properly by stabilizing TOMM6 protein levels and activity. Rather than introducing foreign molecules that disrupt cellular processes, the compounds facilitate the cell's natural protein import functions, allowing mitochondria to self-regulate their protein composition and maintain proper function. This self-service approach reduces the risk of adverse effects.
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention is directed to a TOMM6 (Translocase of Outer Membrane 6kDa subunit homologue; Mitochondrial import receptor subunit TOM6 homolog)-interacting plant or fungal extract comprising an anthraquinone or anthraquinone derivative, a TOMM6-interacting anthraquinone or anthraquinone derivative, and TOMM6-interacting compounds for use in the treatment or prophylaxis of a nervous system disease, atherosclerosis, Hepatitis B infection and/or human papilloma virus (HPV) infection. Furthermore, the present invention relates to a corresponding method of therapeutic or prophylactic treatment of a nervous system disease or disorder, atherosclerosis, Hepatitis B infection and/or human papilloma virus (HPV) infection, as well as to a method for the identification of a TOMM6-interacting compound or composition. Also, the present invention provides a non-human transgenic animal expressing a transgenic, preferably human TOMM6 or a TOMM6 homolog.